Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (131-140 of 386) with videos related to

Pageof 39
Sort By:
JHEP Reports : Innovation in Hepatology|September 2, 2022
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis DAdriana Palom, Ariadna Rando-Segura, Judit Vico, et al.
Antiviral Therapy|September 18, 2015
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapyClara Tmm de Kanter, Maria Buti, Ralph DeMasi, et al.
Journal of Hepatology|October 21, 2019
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antiviralsMònica Pons, Sergio Rodríguez-Tajes, Juan Ignacio Esteban, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 22, 2013
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis BRobert Perrillo, Maria Buti, Francois Durand, et al.
Hepatology (Baltimore, Md.)|June 16, 2011
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the futureVincent Di Martino, Carine Richou, Jean-Paul Cervoni, et al.
Gastroenterology|August 7, 2012
Predicted effects of treatment for HCV infection vary among European countriesSylvie Deuffic-Burban, Pierre Deltenre, Maria Buti, et al.
United European Gastroenterology Journal|April 9, 2025
The Growing Burden of Obesity: Addressing a Global Public Health ChallengePatrizia Burra, Elvira Verduci, Jorge Amil Dias, et al.
Journal of Viral Hepatitis|February 24, 2026
Enhancing Chronic Hepatitis B and D Management Through a Tailored Mobile Health Application: Real-World Outcomes From the Adaptation of the NORA AppJudit Romero-Vico, Anna Feliu, Elena Vargas-Accarino, et al.
Scientific Reports|June 18, 2017
Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized miceKatja Giersch, Maria Homs, Tassilo Volz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 25, 2020
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamideLuisa Roade, Alessandro Loglio, Marta Borghi, et al.
Pageof 39

Showing results (131-140 of 386) with videos related to

Sort By:
Pageof 39
JHEP Reports : Innovation in Hepatology|September 2, 2022
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis DAdriana Palom, Ariadna Rando-Segura, Judit Vico, et al.
Antiviral Therapy|September 18, 2015
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapyClara Tmm de Kanter, Maria Buti, Ralph DeMasi, et al.
Journal of Hepatology|October 21, 2019
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antiviralsMònica Pons, Sergio Rodríguez-Tajes, Juan Ignacio Esteban, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 22, 2013
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis BRobert Perrillo, Maria Buti, Francois Durand, et al.
Hepatology (Baltimore, Md.)|June 16, 2011
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the futureVincent Di Martino, Carine Richou, Jean-Paul Cervoni, et al.
Gastroenterology|August 7, 2012
Predicted effects of treatment for HCV infection vary among European countriesSylvie Deuffic-Burban, Pierre Deltenre, Maria Buti, et al.
United European Gastroenterology Journal|April 9, 2025
The Growing Burden of Obesity: Addressing a Global Public Health ChallengePatrizia Burra, Elvira Verduci, Jorge Amil Dias, et al.
Journal of Viral Hepatitis|February 24, 2026
Enhancing Chronic Hepatitis B and D Management Through a Tailored Mobile Health Application: Real-World Outcomes From the Adaptation of the NORA AppJudit Romero-Vico, Anna Feliu, Elena Vargas-Accarino, et al.
Scientific Reports|June 18, 2017
Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized miceKatja Giersch, Maria Homs, Tassilo Volz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 25, 2020
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamideLuisa Roade, Alessandro Loglio, Marta Borghi, et al.
Pageof 39